Media OutReach
Bora Navigates A Transitional 1Q26 And Sets A Strong Foundation For Rest Of The Year
Transformational Acquisitions Expected to Contribute to Long Term Growth Starting 2Q26
HONG KONG SAR – Media OutReach Newswire – 13 May 2026 – Bora Pharmaceuticals (“Bora”; TWSE: 6472; OTCQX: BORAY) today announced its financial results and operational highlights for 1Q2026 and provides full year outlook.
1Q26 Business and Financial Highlights
- The Company reported 1Q26 revenues of NT$4,001 million, down 17.68% sequentially, with basic EPS of NT$0.21. Gross margin stabilized quarter-over-quarter. The quarter reflected temporary slowdown across both businesses: pricing and demand variability in the generics market through January and February left Upsher-Smith’s 1Q26 revenue 18.63% below the trailing four-quarter run rate, while the scheduled annual maintenance of 6 weeks of our Maryland fill-finish facility limited fixed-cost absorption during the quarter, weighed on earnings quality.
- March saw a rebound in both businesses as conditions improved for both the top and bottom lines with steady demand. During the quarter, the Company advanced Maple Grove site ramp-up significantly, with several multi-year CDMO agreements signed or progressing across pharma clients of various sizes. Additionally, the Company continues to win new CDMO business as 12-month rolling backlog arrived at US$315 million. With a healthy order book at North American sites entering the second quarter, we expect fixed-cost leverage to resume, driving profit improvement as utilization builds across the installed asset base. Meanwhile, Upsher-Smith has successfully defended market share and is deploying lifecycle management initiatives that reinforce our ability to set the cadence of sales in a dynamic competitive environment.
- Non-operating loss primarily reflected a wider equity loss from affiliate Tanvex Biopharma, together with higher tax expense driven by annual 1Q recognition of tax from undistributed earnings of the previous year.
- Disciplined OPEX control has driven expenses down 14.87% quarter-over-quarter and 14.41% year-over-year. This signals that resources have settled in as we begin to see advantages in scale; The Company expects ROA and ROIC to trend gradually upward, albeit with some quarter-to-quarter variability as operating leverage builds.
- Board of Directors approved the acquisition of the CDMO business of MacroGenics Inc. (NASDAQ: MGNX), for total consideration of US$122.5 million, leading to a total 12-month rolling backlog upon closing to approximately US$375 million.
- Sunway Biotech’s Board approved the 100% acquisition of Weider Global Nutrition (“WGN”), an iconic Phoenix-based American sports nutrition brand with a strategic Costco U.S. supplier relationship, commercial presence in 60+ countries, and established positions on Amazon and Walmart. The transaction completes Bora Group’s three-platform architecture, namely CDMO, pharma sales, and nutraceuticals operated under our “dual engine” strategy.
- Share capital increased 0.04% during the quarter from employee stock option exercise.
Mr. Bobby Sheng, Chairman of Bora Group, stated, “The beginning of 2026 was eventful and challenging both in the world and at Bora. We have seen supply chain disruptions, inflation from wars, and continuous geopolitical tensions. Yet through it all, Bora Group’s disciplined approach to growth-oriented investment remained unwavering.
Our CDMO business CAPEX-to-revenue ratio reached an all-time high of over 10% in 2025, marking another year of upward progression and bringing the Company to a level comparable with established global CDMO peers. This marked a deliberate shift in where we direct investments from capacity-led expansion that defined our earlier growth chapters to a sharper focus on capability demands and modality, anchored in innovation and technology. Over the past 18 months, we have pursued an ambitious growth trajectory against a dynamic macroeconomic backdrop – recalibrating expectations, sharpening our strategy, and reaffirming long-term plans. The underlying demand environment supports our conviction: global pharma is growing at 5-8% per year, biologics CDMO outsourcing demand at 15%+ and small-molecule outsourcing demand at 8-10%. With our investment foundation now in place, we believe our CDMO business is positioned to compound organically at 13-23% annually.
In the first quarter, we executed a series of organizational adjustments, each aligned to a specific dimension of customer demand. We established the MSAT (Manufacturing, Science and Technology) function within the CDMO business, the R&D backbone of the platform, to deepen scientific and technical capability across our entire client base, an increasingly critical asset as small and mid-sized biotech and pharma clients rethink their supply chain. In parallel, we repurposed the Strategic Enterprise Account Management team into a networked model to serve clients for whom customer proximity is paramount. Together, these capability investments target specific customer pain points and position Bora to navigate the evolving political and economic landscape and capture a new chapter of commercial momentum.
To sum up, CDMO business in 1Q26 delivered US$27.2 million in total external wins on top of orders on hand, 60% or 7 molecules from pre-commercial programs. For context, full-year 2025 saw 16 pre-commercial molecule signings; 1Q26 alone has already secured nearly half that count in a single quarter. This run-rate acceleration is a leading indicator: as our capability investments take hold, forward visibility and growth potential are set to compound. Bora’s CDMO business has entered a new phase. Reinforcing this trajectory, the Group’s recently announced acquisition of MacroGenics’ Rockville, Maryland CDMO facility adds a substantial commercial-stage monoclonal antibody programs backlog and manufacturing expertise to the Group. Equipped with five 2,000-liter and two 500-liter single-use bioreactors and integrated QC and analytical labs and currently generating more than half of revenues from commercial manufacturing, the transaction marks a pivotal step in scaling Bora’s integrated biologics CDMO platform, known as Bora Biologics. DS and DP capabilities shall be integrated over the next 12–18 months to offer global biotech customers a single partner from development through commercial supply in the U.S..
On the pharma sales side, the Group faced competition across a handful of core generic products. Upsher-Smith is navigating the competitive landscape with a clear focus on the most margin-accretive opportunities while continuing to scout niche, brand-oriented assets. Near-term, DLS market share has been defended; over the medium term, sustained market share maximization of the infantile spasm franchise coupled with swift pipeline replenishment weighted toward differentiated assets is critical. In the first quarter, we saw unique patients for VIGAFYDE grew by more than 140% over same period last year and a continuous increase in new patients. Both healthy signs of steady execution pace building up to durable resilience in the pharma sales business.”
1Q26 Operational Achievements & 2026 Outlook
Global CDMO Operations
Revenues declined 24.62% year-over-year and 30.15% quarter-over-quarter including internal orders, mainly due to above-mentioned maintenance at fill and finish facility in Maryland, a routine cycle factored into our operating plan, and seasonality at Canada site. To scale biologics CDMO one-stop-shop platform in commercialized projects with SUB (Single Use Bioreactors) in the US; Board of Directors approved the acquisition of Rockville, Maryland based drug substance facility from MacroGenics for US$122.5 million.
Following closing, Bora Group intends to leverage the Rockville Site in cooperation with Tanvex Biopharma (TWSE: 6541), which operates the Group’s biologics CDMO franchise under the “Bora Biologics” brand. Together with Bora’s sterile drug product capabilities, this is expected to expand and strengthen the Group’s end-to-end biologics platform. The Rockville facility has operated as an outsource manufacturing partner since 2022 and is equipped with five 2,000-liter and two 500-liter single-use bioreactors and fully integrated QC and analytical laboratories and has been inspected by both the U.S. FDA and Japan’s PMDA.
During the quarter, 0.44 billion doses, or 108 molecules, were developed and manufactured. Excluding internal orders, the business accounted for 37.73% of consolidated revenues. Contribution from the top 20 global pharmaceutical companies stood at 32.10%.
As the Company continues to expand its CDMO capacity and capabilities, this year’s CAPEX plan is closely linked to the contracting cadence of a key customer anchored at Bora’s North American CDMO network. The Group expects to complete Maple Grove’s capital expenditure program in the first half of the year, sequencing the investment to grow in step with major pharmaceutical partners’ supply chain plans and optimize return on capital deployed.
Pharma Sales Operations
Discontinued operations impact in 2025 has materially abated this quarter, positioning Upsher-Smith to re-accelerate organic growth in 2026. Management has defined two strategic priorities for 2026, designed to enhance capital efficiency and sharpen commercial focus:
First, R&D capital allocation optimization. 505(b)(2) Pipeline programs have been transferred to Salus Therapeutics, an equity-method affiliate. Under this structure, Upsher-Smith retains the right to economic participation in commercial outcomes while shareholders’ exposure to early-stage development and regulatory risks, and associated cash burden is meaningfully reduced. The decision is consistent with the Group’s capital discipline observed across businesses.
Second, institutionalizing pipeline expansion capabilities. An integrated business development and medical affairs function is being established to systematically evaluate in-licensing, co-promotion, and bolt-on opportunities. This integrates Bora’s proven asset-selection and M&A strategy directly into Upsher-Smith’s commercial infrastructure, enabling franchise compounding through targeted external sourcing rather than capital-intensive internal development. These lifecycle initiatives focus but are not limited to pediatric epilepsy opportunities.
Collectively, Management expects Upsher-Smith to evolve fully into a capital efficient, commercially led, and therapeutically centered vehicle designed to deliver sustained shareholder value before exiting 2026.
Recent Investor Conference
Bora will host English online earnings call at 7:30 a.m. Taiwan time on May. 14th, 2026. The event will cover the Company’s 1Q26 financial and business results and 2026 outlook.
English Online Earnings Presentation Link: https://events.q4inc.com/attendee/372103448
Bora will participate in 2026 Yuanta Securities Investment Forum in June. For 1:1 meetings with management, please contact your Yuanta representative.
Bora 2026 Earnings Schedule
Q2 2026: Expected in the 2nd week of Aug 2026
Q3 2026: Expected in the 2nd week of Nov 2026
Q4 2026: Expected in the 2nd week of Mar 2027
Hashtag: #BoraPharmaceuticals
The issuer is solely responsible for the content of this announcement.
About Bora
Founded in 2007, Bora Pharmaceuticals (“Bora” or “the Company”, 6472.TW and BORAY.OTCQX) is a leading pharmaceutical services company with a vision and goal of “Contributing to Better Health All Over the World”. Operating under a “Dual Engine” model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients’ quality of life.
By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success “certain,” Bora sets new standards in the pharmaceutical and CDMO industries.
For more, please visit:
https://www.bora-corp.com
https://www.boracdmo.com
Disclaimer:
This document and the accompanying information may contain forward-looking statements. All statements regarding the company’s future business operations, potential events, and prospects (including but not limited to forecasts, targets, estimates, and operational plans) are considered forward-looking statements unless they refer to factual occurrences. Forward-looking statements are subject to various factors and uncertainties that may cause significant differences from actual results, including but not limited to price fluctuations, actual demand, exchange rate variations, market share, competitive conditions, changes in the legal, financial, and regulatory framework, international economic and financial market conditions, political risks, cost estimates, and other risks and variables beyond the company’s control. These forward-looking statements are based on current predictions and assessments, and the company disclaims any responsibility for future updates.
Media OutReach
Bank of China (Hong Kong) x Television Broadcasts Limited (“TVB”) “Wealth Management Expo 2026” was Successfully Held
Empowering Enterprises to Go Global, Pioneering the Blue Ocean of Silver Economy
HONG KONG SAR – Media OutReach Newswire – 27 June 2026 – The “Wealth Management Expo 2026”, powered by Bank of China (Hong Kong) (“BOCHK”) and organised by TVB under the theme of “Empowering Enterprises to Go Global, Pioneering the Blue Ocean of Silver Economy”, was successfully held today. The Expo featured top-tier financial experts and prominent figures for market pulse insights and visionary perspectives on the international landscape, the international use of RMB, enterprises going global, silver economy and wealth management.
The Expo was officiated by Mr. Michael WONG, GBS, JP, Acting Financial Secretary of the HKSAR Government; Mr. Christopher HUI, GBS, JP, Secretary for Financial Services and the Treasury of the HKSAR Government; and Mr. Stephen CHAN, Deputy Chief Executive of BOCHK. Mr. Christopher HUI also shared at the opening forum on how Hong Kong as a global offshore RMB hub supports enterprises in going global. Other attending guests included Dr. KO Wing Man, GBS, JP, Standing Committee of the National Committee of the CPPCC; Mr. SIU Sai Wo, General Manager (Business Operations) of TVB; and representatives from BOCHK.
Mr. Stephen CHAN, Deputy Chief Executive of BOCHK, said in his opening remarks, “This year marks the inaugural year of the nation’s 15th Five-Year Plan, which clearly supports Hong Kong in strengthening its role as an international asset and wealth management centre. Against this backdrop, Hong Kong, as a vital bridge between the Chinese Mainland and the rest of the world, is set to tap into an unprecedented opportunity for growth. Bank of China (Hong Kong) will actively align with national policies and the HKSAR Government’s direction by deepening its regional business development and promoting the international use of RMB, while continuing to fulfil its corporate social responsibilities, contributing to the consolidation of Hong Kong’s position as an international financial centre.”
Opening Forum: Experts Shared Insights on RMB Empowering Enterprises to Go Global
The opening forum of the Expo “New Opportunities in Global Wealth Investment: RMB Empowering Enterprises to Go Global” featured Mr. Christopher HUI, GBS, JP, Secretary for Financial Services and the Treasury, HKSAR Government; Mrs. Pauline NGAN, BBS, JP, Deputy Chairman and Managing Director of Mainland Headwear Holdings Limited, Member of the National Committee of the CPPCC; Mr. Sam YU, Chairman of Hong Kong Investment Funds Association; and Mr. Jack YANG, RMB Business Executive Director of BOCHK. They engaged in an in-depth discussion on the international market trends, enterprises going global and the international use of RMB, elaborating new investment opportunities.
Summit Forum: Decoding Silver Economy Opportunities and Industry Integration
The growing silver-haired population is driving demand across a range of areas, including health, lifestyle and wealth management. Held under the theme “Redefining Value in the Silver Age: Uncovering Blue Ocean Market Opportunities”, the summit forum featured Dr. KO Wing Man, GBS, JP, Standing Committee of the National Committee of the CPPCC; Mr. Angus CHAN, Director of Elderly Care Services of Chinachem Group; Mr. Terry WONG, Chief Executive Officer of Hong Kong Science and Technology Parks Corporation; and Mr. Wilson TANG, Chief Executive of BOC Group Life Assurance Company Limited. Drawing on a macro perspective on industry structure, the speakers analysed the business opportunities within the silver economy and explored how to drive supply chain transformation and integration across traditional industries such as healthcare and insurance, while offering a forward-looking view of the immense potential of this emerging market.
Thematic Workshops and Immersive Digital Experience Zone, Showcasing Comprehensive Wealth Growth Strategies
The Expo also held several thematic workshops, in which experts analysed prevailing topics, including global fund and equity market conditions, retirement wealth planning, and emerging markets, equipping clients with insights into wealth growth strategies. Two fund workshops focused respectively on emerging markets and global income opportunities. The first workshop, “Focusing on Emerging Value in Asia: Embarking on a New Chapter for RMB Assets and China’s Equity and Bond Markets”, examined how the Chinese Mainland’s deepening cooperation with ASEAN, the Global South, and Belt and Road Initiative partner countries is generating new investment opportunities in emerging markets. The workshop also offered an investment outlook of the implications of the National 15th Five-Year Plan and the shifting global landscape for RMB assets and the Chinese Mainland’s equity and bond markets. The second fund workshop, “Harnessing Multi-Asset Strategies to Capture Asia-Pacific Income Opportunities,” explored how investors should diversify asset portfolio amid heightened volatility in global equity and bond markets, while capturing income opportunities from Asia-Pacific and emerging markets.
The retirement planning workshop, “Forward-Looking Wealth Planning: Charting Your Own Path to a Premium Retirement”, addressed the retirement pain points commonly faced by Hong Kong residents, offering financial advice for the silver generation to build a solid safety net for themselves and their families. The equities workshop, “Navigating 2026: Decoding Stock Market Strategies”, dissected global equity market performance and explored how different financial products can be used to balance aggressive and defensive positioning to capture markets with growth potential. The wealth management workshop, “AI-led Future: Blue Ocean Opportunities in Southeast Asia and New Horizons for Enterprises Going Global”, examined the AI investment boom and analysed the unique edge of Hong Kong as a “super value-adder” for enterprises going global.
A 3D immersive digital experience zone highlighted BOCHK’s capabilities across its expansive network reach, anti-fraud education, professional services, digital innovation leadership and award-winning credentials.
BOCHK Private Wealth also officially unveiled its new Wealth+ service proposition at the event, expanding its scope beyond wealth management to encompass multi-dimension of clients’ lives, including lifestyle experiences, family financial planning and holistic well-being, with a commitment to addressing client’s unique and individual needs.
The “Wealth Management Expo 2026” concluded successfully with fruitful outcomes. Through a full day of engaging forums, workshops, digital experience zone and sponsored booths, industry professionals, investors and the public can gain insights into global opportunities, keep abreast of the latest development in the international use of RMB and the strategic advantages of enterprises going global, while capitalising on the diverse opportunities presented by the silver economy, and mastering financial management and wealth growth.
Hashtag: #WealthManagementExpo2026
The issuer is solely responsible for the content of this announcement.
Media OutReach
Vinmec Launches Vietnam’s First Integrated High-Tech Robotic Surgery Network, Establishing the Country’s First Multi-Connected Robotic Surgery Ecosystem
The defining feature of the new network is Vietnam’s first and only multi-connected robotic surgery ecosystem. Rather than deploying standalone robotic systems, Vinmec has established an integrated operating platform that brings together multiple world-leading robotic technologies across its hospital network. Vinmec Times City International Hospital serves as the clinical coordination hub, linking robotic surgery centers at Vinmec Smart City, Vinmec Da Nang, Vinmec Central Park, Vinmec Can Tho and other Vinmec hospitals throughout the country.
For general surgery, Vinmec operates three of the world’s leading robotic surgery platforms: Da Vinci Xi at Vinmec Times City, Hugo RAS at Vinmec Da Nang and Vinmec Central Park, and Toumai MT-1000 at Vinmec Smart City and Vinmec Can Tho. Together, these technologies enable surgeons to access deep anatomical structures, perform highly precise procedures within confined surgical spaces, and select the most appropriate platform based on each patient’s condition. Notably, the Toumai MT-1000 also introduces the capability for 5G-enabled remote robotic surgery, laying the foundation for future models of connected healthcare delivery.
In orthopedic surgery, Vinmec has deployed a comprehensive portfolio of next-generation joint replacement robots, including ROSA at Vinmec Smart City, MISSO at Vinmec Times City and Vinmec Can Tho, and CORI across Vinmec Ocean Park 2, Hai Phong, Da Nang, Central Park, Phu Quoc and Nha Trang. These technologies enable personalized surgical planning based on each patient’s anatomy while supporting millimeter-level precision in implant positioning and joint balancing, helping optimize clinical outcomes and accelerate postoperative recovery.
For neurosurgery and spine surgery, Vinmec has integrated the StealthStation S8, Mazor X Stealth Edition robotic guidance system and the O-arm with StealthStation O2 imaging platform at Vinmec Smart City and Vinmec Da Nang. This advanced technology suite provides real-time navigation, intraoperative imaging and continuous surgical verification, enabling surgeons to accurately access complex anatomical structures while improving procedural safety and reducing the risk of complications.
Complementing its advanced technology ecosystem, Vinmec is also the first healthcare provider in Vietnam to develop a “3-in-1” robotic surgery model built on Personalization, Automation and Standardization. Every patient receives an individualized treatment plan through preoperative 3D reconstruction and surgical simulation, benefits from AI-enabled robotic assistance during surgery, and is treated according to internationally recognized standards in clinical practice, education and research.
Technology delivers value only when placed in the hands of highly skilled professionals. To operate this large-scale robotic surgery ecosystem, Vinmec has developed a multidisciplinary team of specialists who have undergone rigorous training, competency assessments and international robotic surgery certification programs. Their expertise forms the foundation for delivering safe, high-quality and consistently effective surgical care.
Alongside the launch of the robotic surgery network, Vinmec also announced the establishment of the Robotic Surgery Patient Support Fund, backed by nearly VND 300 billion in funding from Vingroup. The fund is expected to reduce financial barriers and expand patient access to advanced robotic surgery, particularly for those facing financial hardship.
At the event, Prof. Tran Van Thuan, MD, PhD, Deputy Minister of Health, remarked: “I highly appreciate Vinmec’s vision of not only investing in advanced medical equipment but also building a comprehensive ecosystem encompassing clinical care, medical education, scientific research, technology transfer, and international collaboration.” The Deputy Minister also acknowledged the humanitarian value of the Robotic Surgery Patient Support Fund, which helps expand access to advanced surgical technologies for eligible patients.
Speaking at the launch ceremony, Prof. Tran Trung Dung, MD, PhD, Chief Executive Officer of Vinmec Healthcare System, said:
“Our High-Tech Robotic Surgery Network is built on a model of multidimensional connectivity connecting experts, hospitals and the world’s leading technology partners within a single integrated ecosystem. Our goal is to provide patients in Vietnam with access to the most advanced surgical innovations while progressively positioning Vietnam as a regional destination for high-tech healthcare and precision surgery.”
According to Assoc. Prof. Pham Van Binh, MD, PhD, Director of the Vinmec High-Tech Robotic Surgery Network, the true strength of the centers lies not only in their advanced robotic systems but also in their ability to transform technology into sustainable clinical excellence.
“Our vision extends beyond building a treatment center. We are establishing an academic institution for robotic surgery that integrates clinical practice, academic training, scientific research and technology transfer, bringing together leading robotic surgeons from Vietnam and around the world.”
The launch of Vinmec’s High-Tech Robotic Surgery Network represents not only a significant milestone in the healthcare system’s development but also an important step forward in accelerating Vietnam’s transition toward an era of precision, personalized and technology-driven surgery. By bringing world-class surgical innovation closer to patients, Vinmec is laying the foundation for Vietnam to emerge as a new regional hub for robotic surgery and advanced medical treatment in Southeast Asia.
Hashtag: #Vinmec
The issuer is solely responsible for the content of this announcement.
The result is a range built to dominate anything from AAA gaming at 4K to AI workloads and content creation, regardless of which form factor suits you best.
Choosing the right Razer Blade laptop in 2026 between the Blade 14, Blade 16 and Blade 18 comes down to what kind of gamer, creator or AI developer you are and what you want out of your laptop: portability or maxed out performance.
Quick Answer: The Right Razer Blade For Every Type of User
- Razer Blade 14: The ideal pick if you game anywhere and value portability and battery life above all else. Built for gamers with things to do and places to be.
- Razer Blade 16: A balanced pick. Slim enough to commute with, powerful enough to skip a desktop. Best for gamers and creators who want the most possible performance in a premium but portable gaming laptop.
- Razer Blade 18: The closest a laptop comes to replacing a full gaming tower or AI dev workstation. For hardcore gamers and AI developers who demand breakthrough performance and the best of the best.
2026 Razer Blade 14 vs 16 vs 18 Laptop Comparison at a Glance: Specs, Use Cases and More
| Spec | Razer Blade 14 (2026) | Razer Blade 16 (2026) | Razer Blade 18 (2026) |
| Graphics | Up to NVIDIA® GeForce RTX™ 5070 (Up to 115W TGP) | Up to NVIDIA® GeForce RTX™ 5090 Laptop GPU, 24GB GDDR7 (Up to 165W TGP) | Up to NVIDIA® GeForce RTX™ 5090 Laptop GPU, 24GB GDDR7 (Up to 175W TGP) |
| Processor |
|
|
|
| Display |
|
|
or
|
| Memory | Up to 32 GB LPDDR5X 8000 MHz (Soldered) | Up to 64 GB LPDDR5X 9600 MHz (Soldered) | Up to 128 GB DDR5 6400 MHz (Slotted) |
| Storage | Installed
|
Installed
Expandable
|
Installed
or
Expandable Supports PCIe SSDs, each slot upgradeable to 8 TB SSD (Dual Sided M.2)
|
| Weight | 1.63 kg / 3.59 lbs | 2.14 kg / 4.71 lbs |
|
| Dimensions |
|
|
or
|
| Battery |
|
|
or
|
| Color |
|
|
|
| Price | From US$2,299 – US$2,899 | From US$2,399 – US$5,599 | From US$3,499 – US$6999 |
| Best For | Gamers on the move who want flagship-tier portability and battery life without giving up serious GPU power. | Gamers and creators who want flagship performance and a class-leading 240 Hz OLED in a chassis they can still commute with | Hardcore gamers, AI developers and pro creators who want desktop-class performance, upgradeable RAM and storage in a portable form factor |
*Spec ranges reflect the highest configurations available at the time of writing. Razer rotates configurations periodically, so please confirm your exact build before buying.
Razer Blade 14: For Gamers on the Move
The Blade 14 is built for the gamer who refuses to choose between portability and proper gaming performance. Daily commuters, students, frequent travellers and creators who want to work and play from anywhere are the natural fit. If your laptop spends real time in a bag, this is the Blade for you.
- Genuine all-day portability: At 1.63kg/3.59 lbs and just 0.62 inch thin, you won’t have to remove anything from your bag to carry the Blade 14
- Massive battery life for a svelte gaming laptop: Packing a 72 Wh battery, the Razer Blade 14 is good for a full day of work or play on a single charge.
- Enough power on the move: The RTX 5070 and AMD Ryzen AI 9 365 handle modern AAA titles with ease, plus AI workloads via the 50 TOPS NPU
- Calman Verified OLED display: A 120 Hz refresh rate that’s smooth enough for most games, with the colour accuracy creative work demands
Explore the Razer Blade 14.
Razer Blade 16: The Travel-Ready All-Rounder
The Blade 16 is for the user who wants flagship performance without committing to a desktop replacement form factor. Streamers running OBS alongside competitive titles, creators handling 4K video and AI-accelerated workflows and gamers chasing a true 240 Hz OLED experience on the go all fit the profile. It’s the model that gets recommended most often, and the 2026 generation strengthens the case.
- Flagship-class performance: The RTX 5090 hits 160 W TGP and pairs with the AMD Ryzen AI 9 HX 370 to push AAA games and AI workloads past what most desktops achieve at QHD.
- The display that does it all: A 16-inch QHD+ OLED at 240 Hz with VESA TrueBlack 1000 HDR and Calman Verified colour, capable of displaying competitive-gaming levels of framerates and creator-grade colour accuracy at the same time.
- The fastest laptop memory shipping today: Up to 64 GB of LPDDR5X-9600 MHz means dozens of browser tabs, OBS, your game and a Premiere timeline can all stay open without anything stuttering.
- Travel-ready flagship: At 14.9 mm and 2.14kg/4.71 lbs, the Blade 16 fits a regular sleeve, and Thunderbolt 5 plugs it straight into a full desktop setup when you’re back at base.
Explore the Razer Blade 16.
Razer Blade 18: Desktop-Class Performance for Power Users
The Blade 18 is built for users who want desktop-class performance without completely trading mobility. The natural audience includes professional creators editing 4K footage, hardcore gamers chasing high frame rates and developers running VMs or AI training jobs. It’s the right pick if you’d rather have one machine that handles everything than maintain a desktop and a separate laptop.
- Desktop-grade silicon: A 24-core Intel Core Ultra 9 290HX Plus paired with an RTX 5090 at 175 W TGP runs AI training, 4K rendering and maxed-out AAA gaming without throttling.
- Swap and expand your memory and storage: The only Blade with slotted DDR5 RAM (up to 128 GB) and two M.2 NVMe slots (up to 8 TB), so your Razer Blade can grow with your project files, AI model weights or game library.
- A desktop display in a laptop: The 18-inch dual-mode panel runs UHD+ at 240 Hz for content creation or FHD+ at 440 Hz for competitive gaming.
- Sustained performance under marathon workloads: Triple-fan vapor chamber cooling handles hour-long renders, AI training runs and ranked sessions without throttling, with overclocking support in Razer Synapse when you want to push further.
Pick Your Razer Blade for 2026
The 2026 Razer Blade lineup offers three distinct paths: maximum portability with the Blade 14, balanced flagship power with the Blade 16 and desktop-class performance with the Blade 18. Whichever fits your style of play, there’s a Blade with your name on it.
Browse all Razer Gaming Laptops to see current configurations and pricing for the Razer Blade and more.
Hashtag: #razer #razerblade #razerblade14 #razerblade16 #razerblade18 #gaminglaptop
The issuer is solely responsible for the content of this announcement.
About Razer
Razer™ is the world’s leading lifestyle brand For Gamers. By Gamers.
The triple-headed snake trademark of Razer is one of the most recognized logos in the global gaming and esports communities. With a fan base that spans every continent, the company has designed and built the world’s largest gamer-focused ecosystem of hardware, software and services.
Razer’s award-winning hardware includes high-performance gaming peripherals and Blade gaming laptops.
With over 200 million users, Razer’s software platform includes Razer Synapse (an Internet of Things platform), Razer Chroma RGB (a proprietary RGB lighting technology system supporting thousands of devices and hundreds of games/apps), and Razer Cortex (a game optimizer and launcher).
Razer also offers payment services for gamers, youth, millennials and Gen Z. Razer Gold is one of the world’s largest game payment services, and Razer Fintech provides fintech services in emerging markets.
Founded in 2005, Razer is dual headquartered in Irvine, California and Singapore, with regional headquarters in Hamburg and Shanghai and 19 offices worldwide.
-
Feature/OPED6 years agoDavos was Different this year
-
Travel/Tourism10 years ago
Lagos Seals Western Lodge Hotel In Ikorodu
-
Showbiz3 years agoEstranged Lover Releases Videos of Empress Njamah Bathing
-
Banking8 years agoSort Codes of GTBank Branches in Nigeria
-
Economy3 years agoSubsidy Removal: CNG at N130 Per Litre Cheaper Than Petrol—IPMAN
-
Banking3 years agoSort Codes of UBA Branches in Nigeria
-
Banking3 years agoFirst Bank Announces Planned Downtime
-
Sports3 years agoHighest Paid Nigerian Footballer – How Much Do Nigerian Footballers Earn